112 related articles for article (PubMed ID: 7789721)
1. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats.
Ohno Y; Ishida K; Ishibashi T; Ikeda K; Kato T; Nakamura M
Gen Pharmacol; 1995 May; 26(3):489-94. PubMed ID: 7789721
[TBL] [Abstract][Full Text] [Related]
2. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions.
Hirose A; Kato T; Ohno Y; Shimizu H; Tanaka H; Nakamura M; Katsube J
Jpn J Pharmacol; 1990 Jul; 53(3):321-9. PubMed ID: 1975278
[TBL] [Abstract][Full Text] [Related]
4. Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats.
Ohno Y; Ishibashi T; Okada K; Ishida K; Nakamura M
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Oct; 19(6):1091-101. PubMed ID: 8584685
[TBL] [Abstract][Full Text] [Related]
5. Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats.
Maruoka Y; Ohno Y; Kato T; Hirose A; Tatsuno T; Nakamura M
Jpn J Pharmacol; 1993 Aug; 62(4):419-22. PubMed ID: 7901446
[TBL] [Abstract][Full Text] [Related]
6. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum.
Ishibashi T; Ikeda K; Ishida K; Yasui J; Tojima R; Nakamura M; Ohno Y
Eur J Pharmacol; 1996 May; 303(3):247-51. PubMed ID: 8813576
[TBL] [Abstract][Full Text] [Related]
7. Central 5-HT(4) receptors and dopamine-dependent motor behaviors: searching for a functional role.
De Deurwaerdère P; Cervo L; Stinus L; Spampinato U
Pharmacol Biochem Behav; 2002 Apr; 71(4):627-33. PubMed ID: 11888554
[TBL] [Abstract][Full Text] [Related]
8. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
Gulati A; Srimal RC; Dhawan BN
Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
[TBL] [Abstract][Full Text] [Related]
9. Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds.
Ishizumi K; Kojima A; Antoku F; Saji I; Yoshigi M
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2139-51. PubMed ID: 8582016
[TBL] [Abstract][Full Text] [Related]
10. Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioral hypersensitivity in the rat.
Kinon BJ; Merson D; Kane JM
Psychopharmacology (Berl); 1984; 84(3):347-51. PubMed ID: 6440181
[TBL] [Abstract][Full Text] [Related]
11. Phencyclidine-induced dopamine-dependent behaviors in chronic haloperidol-treated rats.
Yamaguchi K; Nabeshima T; Amano M; Yoshida S; Furukawa H; Kameyama T
Pharmacol Biochem Behav; 1985 Nov; 23(5):803-9. PubMed ID: 4080767
[TBL] [Abstract][Full Text] [Related]
12. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia.
Gattaz WF; Emrich A; Behrens S
J Neural Transm Gen Sect; 1993; 92(2-3):197-201. PubMed ID: 8369109
[TBL] [Abstract][Full Text] [Related]
13. Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Nakamura M
Pharmacol Biochem Behav; 1997 Aug; 57(4):889-95. PubMed ID: 9259021
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
15. Effects of buspirone on dopaminergic supersensitivity.
Queiroz CM; Frussa-Filho R
Life Sci; 1997; 61(4):371-82. PubMed ID: 9244363
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
17. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
De Veaugh-Geiss J; Devanand DP; Carey RJ
Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
[TBL] [Abstract][Full Text] [Related]
18. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
Surmann A; Havemann-Reinecke U
J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
[TBL] [Abstract][Full Text] [Related]
19. Scopolamine modulates apomorphine-induced behavior in rats treated with haloperidol or SCH 23390.
Butkerait P; Friedman E
Eur J Pharmacol; 1988 Mar; 148(2):269-72. PubMed ID: 2897925
[TBL] [Abstract][Full Text] [Related]
20. 8-OH DPAT can restore the locomotor stimulant effects of cocaine blocked by haloperidol.
Carey R; Damianopoulos E; De Palma G
Pharmacol Biochem Behav; 2000 Aug; 66(4):863-72. PubMed ID: 10973527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
